Clinical Study

Nrg-Hn004- Randomized Phase II/III Trial Of Radiotherapy With Concurrent Medi4736 (Durvalumab) Vs. Radiotherapy With Concurrent Cetuximab In Patients With Stage III-Ivb Head And Neck Cancer With A Contraindication To Cisplatin

Posted Date: May 15, 2019

  • Investigator: Jordan Kharofa
  • Specialties: Cancer, Head and Neck Cancer, Oncology
  • Type of Study: Drug

To determine the safety and effectiveness of radiotherapy (RT) with concurrent and adjuvant anti-PD-L1 therapy [MEDI4736 (durvalumab)] is safe in patients with locoregionally advanced head and neck cancer (HNC) who have a contraindication to cisplatin.

Criteria:

To Be Eligible: Must Have Diagnosed Advanced Hnscc With Contraindiction To Cisplatin, Must Be 18 Years Or Older, Bodyweight >30Kg, No Prior Malignancy In <3 Years

Keywords:

Head And Neck Cancer, Phase Ii/Iii

For More Information:

Uc Cancer Institute
513-584-7698
cancer@uchealth.com


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.